Fabry disease due to D313Y variant with renal failure and possible cardiac involvement: a case report
Open Access
- 30 April 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 7 (5) , ytad224
Abstract
This is a case report of a patient with Anderson–Fabry disease (AFD) due to the D313Y variant on the a-galactosidase A (GLA) gene on migalastat treatment and severe chronic kidney disease referred to our unit to assess possible cardiac involvement. A 53-year-old man with chronic kidney disease due to AFD and a medical history of revascularized coronary artery disease, chronic atrial fibrillation, and arterial hypertension was referred to our unit for evaluation of possible cardiac involvement in the context of AFD. Biochemical evaluation reported reduced serum alpha-galactosidase A activity and borderline abnormal serum lyso-Gb3 enzyme activity. The patient had also history of acroparesthesias, dermatological presentation of multiple angiokeratomas, severe kidney impairment with an estimated glomerular filtration rate (eGFR) of 30 mL/min/1.73m² by the age of 16, and microalbuminuria that cumulatively set the diagnosis of AFD. Transthoracic echocardiogram showed left ventricular concentric hypertrophy with left ventricular ejection fraction of 45%. Cardiac magnetic resonance showed findings in keeping with ischaemic heart disease (IHD), i.e. akinesia and subendocardial scarring of the basal anterior and the entirety of the septum and the true apex; in addition, there was severe asymmetrical hypertrophy of the basal anteroseptum (max 18 mm), evidence of low-grade myocardial inflammation, and mid-wall fibrosis of the basal inferior and inferolateral wall, suggesting a cardiomyopathic process–myocardial disease which could not be explained solely by IHD or well-controlled hypertension. This is the first case of possible cardiac involvement in a patient with AFD due to the D313Y variant. This case demonstrates the diagnostic challenges of cardiac involvement in AFD, especially in the presence of a concomitant underlying pathology.Keywords
This publication has 5 references indexed in Scilit:
- The mutation D313Y may be associated with nervous system manifestations in Fabry diseaseJournal of the Neurological Sciences, 2020
- Is the alpha‐galactosidase A variant p.Asp313Tyr (p.D313Y) pathogenic for Fabry disease? A systematic reviewJournal of Inherited Metabolic Disease, 2020
- The D313Y variant in theGLAgene – no evidence of a pathogenic role in Fabry diseaseScandinavian Journal of Clinical and Laboratory Investigation, 2017
- Fabry disease due to D313Y and novel GLA mutationsBMJ Open, 2017
- An Atypical Variant of Fabry's Disease in Men with Left Ventricular HypertrophyNew England Journal of Medicine, 1995